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Abstract
Background: Astrocytomas are the most common and aggressive brain tumors characterized by their highly
invasive growth. Gain of chromosome 7 with a hot spot at 7q32 appears to be the most prominent aberration in
astrocytoma. Previously reports have shown that microRNA-335 (miR-335) resided on chromosome 7q32 is
deregulated in many cancers; however, the biological function of miR-335 in astrocytoma has yet to be elucidated.
Results: We report that miR-335 acts as a tumor promoter in conferring tumorigenic features such as growth and
invasion on malignant astrocytoma. The miR-335 level is highly elevated in C6 astrocytoma cells and human
malignant astrocytomas. Ectopic expression of miR-335 in C6 cells dramatically enhances cell viability, colony-
forming ability and invasiveness. Conversely, delivery of antagonist specific for miR-335 (antagomir-335) to C6 cells
results in growth arrest, cell apoptosis, invasion repression and marked regression of astrocytoma xenografts.
Further investigation reveals that miR-335 targets disheveled-associated activator of morphogenesis 1(Daam1) at
posttranscriptional level. Moreover, silencing of endogenous Daam1 (siDaam1) could mimic the oncogenic effects
of miR-335 and reverse the growth arrest, proapoptotic and invasion repression effects induced by antagomir-335.
Notably, the oncogenic effects of miR-335 and siDAAM1 together with anti-tumor effects of antagomir-335 are also
confirmed in human astrocytoma U87-MG cells.
Conclusion: These findings suggest an oncogenic role of miR-335 and shed new lights on the therapy of
malignant astrocytomas by targeting miR-335.
Introduction
Astrocytomas derived from astrocytes or astroglial precur-
sors are the most common malignant cancer affecting the
central nervous system, accounting for >60% of primary
brain tumors [1]. Current therapies for astrocytomas
including surgery, radiation, and chemotherapy have not
been successful due to the rapid and invasive tumor
growth, the genetic heterogeneity and our poor under-
standing of the molecular mechanisms governing disease
manifestation and progression [2].
MicroRNAs (miRNAs) are small non-coding RNAs (18
to 25 nucleotides) with potential roles in regulation of
gene expression at posttranscriptional level [3]. Cumula-
tive evidence suggests that deregulation of miRNAs may
contribute to specific human diseases, including cancer. It
has been reported the amplification or overexpression of
implicated microRNAs in cancers could materially serve
as oncogenes [4]. Meanwhile, the tumor suppressing roles
of certain miRNAs have also been presumed due to their
physical deletion or reduced expression in human cancer
[5]. Of note, recent data suggest an advantage of miRNA-
based classification than mRNA profiling in origin identi-
fying [6], novel biomarkers for diagnosis [7,8] and prog-
nosis predicting for cancer patients [9]. Even more,
miRNAs stand for potential promising therapeutic targets
for cancer treatment [7,8,10,11]. These findings provide
new insights into the mechanisms of the tumor biology
and give a novel thought to the therapeutic strategies
It is well established that chromosome 7q32 is a hot
spot that frequently amplified in malignant astrocytomas
[12]. There are 8 miRNAs(miR-593, miR-129-1, miR-335,
miR-182, miR-96, miR-183, miR-29a, miR-29b-1) resided
on this genomic locus, some of which have been investi-
gated, either as oncogenes or tumor suppressor genes
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[13-15]. MiR-335, which is transcribed from the genomic
region chromosome 7q32.2, has been reported to act as a
tumor initiation and metastasis suppressor of breast can-
cer [16,17]. Furthermore, it is also demonstrated that
miR-335 regulates Rb1 and controls cell proliferation in a
p53-dependent manner [18]. In addition, a recent study
has shown that miR-335 orchestrates cell proliferation,
migration and differentiation in human mesenchymal
stem cells [19]. These investigations indicate the impor-
tant roles of miR-335 in tumor initiation and progression;
however, the biological role of miR-335 in malignant
astrocytoma pathogenesis is still largely unknown.
In this study, we aimed to investigate the possible
contributions of miR-335 imbalance to astrocytoma
pathogenesis. We found that miR-335 targeted a poten-
tial tumor suppressor Daam1 in astrocytoma cells,
which promoted several malignant features such as
growth and invasion, whereas miR-335 inhibition could
potently induce growth arrest, apoptosis and invasion
repression both in vitro and in vivo. These findings sug-
gest an oncogenic role of miR-335 in the molecular
etiology of malignant astrocytomas and might provide
new insights into the implication for future cancer
therapy.
Materials and methods
Cell Cultures and Patient Tissues
Rat C6 astrocytoma cells and human U87-MG astrocy-
toma cells were obtained from the American Type Culture
Collection. Human HEB normal astrocytes were obtained
from Guangzhou Institutes of Biomedicine and Health,
Chinese Academy of Sciences (Guangzhou, China). Cell
cultures were performed as described previously [20].
Briefly, cells maintained in DMEM (Invitrogen, USA) sup-
plemented with 10% FBS and a humidified atmosphere of
5% CO2 at 37°C. Rat normal astrocytes were obtained
from Sprague-Dawley rat pups (postnatal 7~8 days). The
first three passage astrocytes were used in our study. Tis-
sue specimens (tumor, adjacent paracancerous tissues) of
malignant astrocytoma patients were collected after
informed consent and immediately frozen in liquid nitro-
gen. The astrocytoma tissues were verified by a pathologist
as WHO grade II-III and the patients’ characteristics were
indicated in Additional file 1 Table S1.
Cell Viability Assay
Cell viability was determined by the 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma,
USA) assay. Briefly, cells were seeded in 96-well plates at
2 × 103 cells/well and incubated overnight. MTT solution
(5 mg/ml in PBS, 20 μl/well) was added to the cells to
produce formazan crystals. MTT solution was substituted
by 150 μl DMSO 4 h later to solubilize the formazan
crystal. The optical absorbance was determined at
490 nm using an iMark microplate reader (Bio-Rad,
USA).
Oligonucleotide Transfection
MiR-335 mimics, negative control (NC), antagomir-335,
antagomir-NC and Daam1 silencing oligonucleotides
(siDaam1) (RiboBio, China) were transfected using Lipo-
fectamine RNAiMAX (Invitrogen) according to manufac-
turer suggested procedures. Transfection efficiency was
evaluated by Cy3-labeled oligonucleotides negative con-
trol (data not shown).
Colony Formation Assay
Colony formation was evaluated as previously described
[21]. Twenty-four hours after transfection, 200~500 trans-
fected cells were placed in a fresh six-well plate and main-
tained in DMEM containing 10% FBS for 7 to 10 days.
Colonies were fixed with methanol and stained with 0.1%
crystal violet in 20% methanol for 15 min, and representa-
tive colonies were photographed.
Cell Invasion Assay
Cell culture chamber with 8 μm pore size polycarbonate
membrane filters (BD Biosciences, USA) were used for
cell invasion assay. The filters were pre-coated with 50 μl
Matrigel (1.25 mg/ml). Cells transfected with respective
RNAs were harvested and seeded 1 × 105 cells/well with
1% FBS medium in upper chambers which were soaked
in the bottom chambers filled with 0.6 ml complete med-
ium. At the same time, equal cells of the each group were
plated to 96-well plates for cell number assay (MTT).
The chamber was incubated at 37°C for 36 h and then
the Matrigel was removed. The invaded cells were fixed
with 4% paraform and stained with hematoxylin before
photography and calculation. The invasiveness of cells
was evaluated by the percentage-of-invasion (invaded cell
number/total cell number × 100%).
Cell-Cycle Analysis
Cells were collected by trypsinization, washed in PBS,
and fixed in 70% ethanol for 30 min at 4°C. After washing
with PBS, cells were incubated with the DNA-binding
dye propidium iodide (50 μg/ml) and RNase (1.0 mg/ml)
for 30 min at 37°C in the dark. Finally, cells were washed
and red fluorescence was analyzed by a FACSCalibur
flow cytometer (BD, Germany) using a peak fluorescence
gate to discriminate aggregates.
Caspase 3/7 Activation Assay, Hoechst Staining, and
TUNEL Assay
For caspase 3/7 activation assay, cells were seeded into
96-well plates at 2 × 105 cells per well and transfected
with antagomir-335 or antagomir-NC at the indicated
concentration for 72 h. Meanwhile, cells with the same
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treatment of each group were plated to 96-well plates for
cell number assay (MTT). Caspase activity was deter-
mined using Caspase-Glo 3/7 Assay (Promega, USA)
according to the manufacturer’s instructions, and evalu-
ated as follows: caspase activity/cell number × 100%.
For Hoechst 33258 staining, cells were fixed with 4% par-
aform for 10 min, stained with Hoechst 33258 (5 ug/ml,
Sigma) for 15 min in the dark, and observed by fluores-
cence microscopy (Olympus, USA) with a 340 nm excita-
tion filter.
For TUNEL assay, apoptotic cells in 4 μm sections of
paraffin-embedded tumor samples or antagomir-335 trea-
ted cells were detected by In Situ Cell Death Detection
Kit-TMR red (Roche, Germany) according to the manu-
facturers’ instructions and the samples were analysed by
fluorescence microscopy (Olympus) with a 540 nm excita-
tion filter. The total number of apoptotic cells was quanti-
fied in 5 randomly selected microscopic fields.
Western Blot Analysis
Western blot was perform as described [22].The following
antibodies were used: antibodies against DAAM1(1:500;
Santa Cruz Biotechnology, USA), GFAP, phosphorylation
(Ser 19) of MLC (1:1,000; Cell Signaling Technology,
USA) and b-actin (1:2,000; New England Biolabs, USA).
Luciferase Assay
The potential binding sites of miR-335 within Daam1 3’-
UTR were obtained by TargetScan and PicTar. Synthetic
oligos including predicted binding sites were annealed then
cloned into Xho I/Not I site of psiCHECK-2 (Promega).
C6 cells were transiently transfected with wide type (WT)
or mutant (MUT) reporter vector and microRNA using
Lipofectmine 2000 (Invitrogen) at the indicated concentra-
tions. Luciferase activity was measured 48 h posttransfec-
tion using the Dual-Luciferase Reporter Assay System
(Promega) followed the manual. Renilla luciferase activity
was normalized to corresponding firefly luciferase activity
and plotted as a percentage of the control.
Real-Time PCR-Based Detection of MiR-335 and Rat
Daam1-mRNA
Total RNA was prepared using TRIZOL reagent (Invitro-
gen). Expression of mature miR-335 was determined by
stem-loop primer SYBR Green quantitive real time-PCR
(qRT-PCR) and normalized to U6. The stem-loop primer
sequence for reverse transcription was as follows: 5’-CTC
AAC TGG TGT CGT GGA GTC GGC AAT TCA GTT
GAG ACA TTT TT-3’. Rat Daam1 mRNA expression was
detected by qRT-PCR and normalized to 18SrRNA. The
generated cDNA was amplified with primers for miR-335
(5’-ACA CTC CAG CTG GGT CAA GAG CAA TAA
CGA AA-3’ and 5’-CTC AAC TGG TGT CGT GGA-3’)
for rat Daam1 (5’-ACT ACT ACA CCA GCA CCA-3’ and
5’-ACT CTC CTC ACT TCC ATG-3’). All qRT-PCR
were performed in triplicates.
In Vivo Assay
For antagomir pretreated study, antagomir-335-and antag-
omir-NC-transfected C6 cells (1 × 106 ) were prepared in
100 μl serum free DMEM medium and then s.c. injected
into either side of the posterior flank of each female
BALB/c athymic 4-week nude mouse. Tumor growth was
monitored by caliper measurement every two days for
2 weeks. Tumor volume (V) was calculated as follows: V =
L × W2 × 0.5; L, length; W, width. Tumor weight was
detected at the end of the study.
For antagomir treatment, 4-week old athymic nude mice
were s.c. injected with 1 × 105 C6 cells; after approxi-
mately 10 days, when tumors became palpable, the tumor-
bearing nude mice were treated with antagomir-335. 50 μl
of antagomir-335 (diluted in PBS at 4 mg/ml), or control
antagomir-NC were injected intratumorally every two
days for 2 weeks. Tumor growth was monitored every two
days for 3 weeks. Tumor volume (V) and weight was cal-
culated as described above.
Confocal microscopy
Cells were grown on glass coverslips to 30% confluence
and transfected with RNAs for 36 h. The mediums were
removed and cells were rinsed with PBS twice. Cells were
fixed with 4% paraformaldehyde for 30 min, washed
three times with PBS and then penetrated and blocked
with PBS containing 0.2% Triton X-100 and 5% bovine
serum albumin for 1 h. The blocking buffer was removed
and incubated with phallotoxins(5 Units/ml, Molecular
probe, USA,) over night at 4°C. Cells were washed three
times with penetrating buffer. Images were photographed
with a Zeiss LSM 510 Confocal Microscope (Carl Zeiss
Microimaging, Thornwood, NY).
Immunohistochemistry
Immunohistochemistry staining of 4 μm sections of paraf-
fin-embedded samples were performed as described [23].
Sections were stained with primary antibody DAAM1
(1:50) overnight at 4°C, bio-anti mouse IgG for 1 h and
then incubated with avidin biotin-peroxidase complex
diluted in NaCl ⁄ Pi.
Statistical Analysis
Data are presented as mean ± SD of three separated
experiments if not noticed. A difference with a P value <
0.05 by ANOVA was considered statistically significant.
Results
MiR-335 is highly expressed in malignant astrocytoma
We found 8 expressed miRNAs (miR-593, miR-129-1,
miR-335, miR-182, miR-96, miR-183, miR-29a, miR-29b-1)
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resided on chromosome 7q32, a hot spot that frequently
gained in astrocytoma(Figure 1A). Among these miRNAs,
miR-335 expression between C6 astrocytoma cells and rat
normal astrocytes was analyzed by qRT-PCR. Interestingly,
the expression of miR-335 was markedly upregulated in C6
cells (Figure 1B). To further confirm and extend this find-
ing, we investigated the expression of miR-335 in a subset
of human astrocytoma tissues. Consistently, we also
observed a significant higher level of miR-335 in astrocy-
toma patient samples with respect to their paracancerous
counterparts (Figure 1B). These results raise a possibility
that miR-335 might be an oncomiRNA in malignant
astrocytoma and might well have a role in malignant astro-
cytoma pathogenesis.
MiR-335 positively regulates viability and invasion of
C6 cells in vitro
To elucidate the potential role of miR-335 in astrocytoma
pathogenesis, we first performed in vitro gain-of-function
analyses by introducing miR-335 mimics into C6 cells.
Ectogenic miR-335 dramatically enhanced cell viability in
dose-and time-dependent manners (Figure 2A, B) and
significantly promoted colony formation (Figure 2C up-
panel, 2D). Moreover, miR-335 overexpression could also
result in marked increase of cell invasiveness (Figure 2E
up-panel, 2F). Notably, miR-335 overexpression failed to
transform but strongly enhanced the oncogenic proper-
ties such as the invasiveness and viability of primary cul-
tured normal astrocytes (Additional file 2 Figure S1).
To determine the consequence of miR-335 inhibition in
astrocytoma cells, we delivered an antagonist specific for
miR-335 (antagomir-335) into C6 cells. Effective miR-335
inhibition strongly suppressed cell growth (Figure 2G, H),
colony formation (Figure 2C down-panel, 2D) and cell
invasion (Figure 2E down-panel, 2F). Importantly, knock-
down of miR-335 exhibited little sign of viability inhibition
on normal astrocytes (Figure 2I), suggesting a specific
anti-tumor effect of miR-335 inhibition. Heretofore, all
the results authentically indicate an oncomiRNA character
of miR-335 as promoting oncogenic phenotypes in
astrocytoma.
MiR-335 abrogation induces apoptosis in C6 cells
The growth-inhibitory effect of antagomir-335 led us to
further investigate whether miR-335 silencing may inhibit
cell proliferation and/or induce apoptosis. By flow cytome-
try analysis, we observed no change on cell cycle distribu-
tion (Figure 3A). Nevertheless, apoptotic cells with
characteristic morphologic alterations such as cell shrink-
age were observed (Figure 3B). Specifically, Hoechst stain-
ing and quantification of the number of cells with
condensed and fragmented nuclei indicated that antago-
mir-335 treated cells underwent apoptosis (Figure 3C, D).
In line with this observation, TUNEL assay also showed
an increased apoptosis in antagomir-335 treated C6 cells
(Figure 3E, F).Furthermore, caspase 3/7 activity was mark-
edly enhanced in a dose-dependent manner after 72 h
antagomir-335 tranfection, confirming miR-335 abroga-
tion-induced apoptosis (Figure 3G). These results suggest
that antagomir-335 induced growth arrest was, at least in
part, caused by apoptosis.
Daam1 is a direct target of miR-335
To identify specific gene targets of miR-335 by which it
might promote oncogenic behaviors, we searched diverse
target prediction databases (TargetScan, Pictar) for
Figure 1 MiR-335 is highly expressed in astrocytoma. (A) A
schematic showing miRNAs located on chromosome 7q32 in
astrocytoma. (B) Data shown are expression level of miR-335 in C6
astrocytoma cells and patient astrocytoma tissues by real-time
quantitative RT-PCR, comparing with their relative normal
counterparts. P, adjacent paracancerous tissues; T, patient
astrocytoma tissues. RNA input was normalized by U6 snRNA. Data
represent the means ± SD of three independent experiments.
Statistical differences compared with the controls are given as **,
P < 0.01; ***, P < 0.001.
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Figure 2 Effects of miR-335 on viability and invasion in C6 astrocytoma cells. (A) Dose-dependent effect of miR-335 mimics on cell
viability. C6 cells were transfected with miR-335 mimics or negative control mimics (NC) for 72 h at the indicated concentrations. (B) Time-
dependent effect of miR-335 mimics on cell viability. C6 cells were transfected with 50 nM miR-335 mimics for the indicated times. (C, D) Colony
formation was observed at the presence of miR-335 mimics (C up-panel) or antagomir-335(C down-panel). (E, F) Cell invasiveness was detected
by transwell invasion assay. C6 cells were transfected with 50 nM miR-335 mimics (E up-panel) or 100 nM antagomir-335 (E down-panel) or their
counterpart negative controls. Graph is the representative of three independent experiments. (G) Dose-dependent effect of antagomir-335 on
cell viability. C6 cells were transfected with antagomir-335 or antagomir-NC for 72 h at the indicated concentrations. (H) Time-dependent effect
of antagomir-335 on cell viability. C6 cells were transfected with 100 nM antagomir-335 for the indicated times. (I) Cell viability was measured
with MTT assay. Rat normal astrocytes and C6 astrocytoma cells were transfected with 100 nM antagomir-335 or antagomir-NC for 72 h. Data
represent the means ± SD. Statistical differences compared with the controls are given as *, P < 0.05; **, P < 0.01; ***, P < 0.001. Original
magnification in (E), 200 ×.
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Figure 3 MiR-335 abrogation induces apoptosis in C6 astrocytoma cells. (A) Cell cycle distribution detection. C6 cells were transfected with
100 nM antagomir-335 or antagomir-NC for 72 h and cell cycle distribution was analyzed by flow cytometer. (B) Phase-contrast imaging and (C)
Hoechest 33258 staining of C6 cells. (D) Quantitation of the percentage of apoptotic cells. (E, F) Apoptotic cells were detected by TUNEL assay.
(G) Dose-dependent effect of antagomir-335 on caspase3/7 activity. C6 cells were transfected with antagomir-335 at the indicated
concentrations for 72 h. Data represent the means ± SD. Statistical differences compared with the controls are given as *, P < 0.05; **, P < 0.01;
***, P < 0.001. Original magnification in (B, E), 200 ×; Original magnification in (C), 640 ×.
Shu et al. Molecular Cancer 2011, 10:59
http://www.molecular-cancer.com/content/10/1/59
Page 6 of 17
theoretical target genes whose downregulation could med-
iate the observed effects of miR-335. Among all the puta-
tive targets, Daam1, Rasa1 and Map2 which we chose for
our further study were known to play important roles in
cell motility or proliferation [24,25]. The predicted miR-
335 binding sites were shown (Figure 4A, Additional file 2
Figure S2). Interestingly, after introducing miR-335 into C6
cells and normal astrocytes, a dramatic downregulation of
DAAM1 protein in a dose-dependent manner was concur-
rent with an unaltered Daam1 mRNA (Figure 4B, C, Addi-
tional file 2 Figure S3), indicating a posttranscriptional
modulation of miR-335 on Daam1. In parallel experiments,
no obvious changes of RASA1, and MAP2 protein levels
could be detected (Additional file 2 Figure S4). Then, a
consistent reduction of luciferase activity of the reporter
that contained wild-type 3’-UTR of Daam1 mRNA was
observed in the condition of extra miR-335 (Figure 4D),
while the luciferase activity of mutant reporter was almost
unaffected. In contrast, the addition of antagomir-335 in
C6 cells increased luciferase activity (Figure 4E), associated
with the upregulation of DAAM1 protein (Figure 4F up-
panel). Importantly, the phosphorylation of MLC (myosin
light chain) which is a downstream factor of DAAM1 and
the direct trigger of apoptosis was strongly induced after
antagomir-335 transfection (Figure 4F down-panel).
To further discern the regulatory role of endogenous
miR-335 in DAAM1 protein expression, we analyzed the
protein level of DAAM1 in C6 cells and normal astrocytes
in which miR-335 level had been detected by qRT-PCR
(Figure 1B). As expected, we observed a sharp reduction
of DAAM1 protein in miR-335-overexpressed C6 cells
(Figure 4G left-panel, 2H). Here, GFAP expression was
used as a biomarker of primary cultured normal astro-
cytes. Importantly, this reciprocal expression pattern was
further confirmed in a set of resected human astrocytoma
tissue samples. As Figure 4G right-panel, 2H shown,
DAAM1 was highly expressed in all of the respective adja-
cent paracancerous fields, but barely detectable in human
astrocytoma tissues, although the degree of low-expression
varied from one sample to another. These data indicate
that miR-335 may inhibit the expression of Daam1 at
posttranscriptional level by directly targeting the 3’-UTR
of Daam1 mRNA.
Knockdown of Daam1 mimics the oncogenic effects of
miR-335 in C6 cells
To determine whether Daam1 is a functional target of
miR-335 in malignant astrocytoma cells, we investigated
whether reduction of Daam1 expression could mimic the
growth and invasion-promoting effects of miR-335. As
Figure 5A shown, knockdown of Daam1 (siDaam1) in C6
cells for 48 h resulted in a major reduction in DAAM1
protein, the repression effect was also observed by miR-
335 transfection. Effective Daam1 silencing could
dramatically stimulate viability and colony formation of
C6 cells, which were similar to that of miR-335 transfec-
tion (Figure 5B, C). Moreover, both miR-335 and
siDaam1 transfected cells showed a dramatic cytoskele-
ton rearrangement characterized by a loss of actin stress
fibers and induction of actin-positive membrane ruffles
(Figure 5D). Accordingly, an enhanced invasiveness was
further observed both in miR-335 and siDaam1 treated
cells (Figure 5E). These findings suggest that Daam1
repression may contribute to the miR-335-induced onco-
genic features.
Knockdown of Daam1 reverses the anti-tumor effects of
antagomir-335 in C6 cells
We further examined whether Daam1 abrogation counter-
acts the anti-tumor effects of antagomir-335. As Figure 6A
shown, siDaam1 effectively abolished the upregulation of
DAAM1 induced by antagomir-335. Interestingly, the
resulting Daam1 knockdown obviously rescued the antag-
omir-335-induced growth arrest, repression of colony for-
mation and invasion (Figure 6B, C, D). Furthermore,
siDaam1 transfectants also significantly decreased the cas-
pase3/7 activity induced by antagomir-335(Figure 6E).
Taken together, all these data suggest that Daam1 is
potentially involved in miR-335-regulated growth and
invasion.
MiR-335 inhibition suppresses tumor growth in vivo
Based on the in vitro studies, we hypothesized that aboli-
tion of miR-335 expression might have anti-tumor effects
in vivo. To address this critical question, we used two
in vivo xenograft models. In pretreated model, as shown in
Figure 7A-C, pre-transfection of antagomir-335 into C6
cells led to a significant reduction in both tumor volume
(Figure 7A, B) and weight (Figure 7C) compared with
antagomir-NC transfectant. Furthermore, to determine
whether inhibition of miR-335 may have therapeutic
effects, C6 cells were injected into nude mice, and tumors
thereby generated were treated with antagomir-335 or
antagomir-NC for two weeks(Figure 7D). In line with
the pretreated model, intratumorally injection of antago-
mir-335 dramatically inhibited tumor growth and weight
(Figure 7E, F). Intriguingly, the ratio of the anterior flank
metastasis was as high as 40% in antagomir-NC group;
however, no metastasis was observed in antagomir-335
group (Additional file 2 Figure S5). Consistently, immuno-
histochemistry showed a marked increase of DAAM1 pro-
tein level in antagomir-335 treated group (Figure 7G). In
addition, TUNEL assay showed an increased apoptosis in
tumors administrated with antagomir-335, as compared to
the control group (Figure 7H). All these results suggest
that miR-335 may confer a survival advantage to astrocy-
toma cells and that it might be a novel potential therapeu-
tic target for malignant astrocytoma therapy.
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Figure 4 Daam1 is a direct target of miR-335. (A) Schematic representation of 3’-UTR of Daam1 mRNA with the putative miR-335 binding
sequence. Mutation was introduced to the Daam1 3’-UTR sequence in the complementary site for the seed region of miR-335. (B, C) Effects of
miR-335 on expression of endogenous DAAM1 protein. Western blot analysis was used to monitor DAAM1 protein expression in rat astrocytes
(B) and C6 cells (C) 72 h after transfection with miR-335 mimics or negative control mimics (NC) at the indicated concentrations. (D, E) Analysis
of luciferase activity. C6 cells were cotransfected with psiCHECK-2-wild type Daam1 3’-UTR/-mutant Daam1 3’-UTR (indicated as WT or MUT on
the × axis), and (D) miR-335 mimics or (E) antagomir-335, luciferase activity was assayed 72 h after transfection. (F) Effects of antagomir-335 on
expression of DAAM1 and phosphorylation of MLC (myosin light chain). C6 cells were transfected with 100 nM antagomir-335 or antagomir-NC,
and applied for western blot analysis 72 h later. (G) DAAM1 protein is significantly downregulated in astrocytoma. Endogenous DAAM1
expression in C6 cells and human astrocytoma tissues were detected by western blot. GFAP expression was used as a biomarker of normal
astrocytes. (H) Quantified protein levels of DAAM1 are shown as normalized by b-actin. Data represent the means ± SD of three independent
experiments. Statistical differences compared with the controls are given as *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 5 SiDaam1 mimics the oncogenic effects of miR-335 in C6 cells. (A) SiDaam1 efficiently inhibited the expression of DAAM1. Western
blot was used to detect the expression of DAAM1 72 h after transfection with 50 nM siDaam1 or miR-335 mimics in C6 cells. (B) Cell viability
was detected by MTT assay. (C) Effect of siDaam1 or miR-335 transfection on colony formation. (D) Morphologic alteration (up-panel) and
phallotoxins stained actin rearrangement (down-panel). Cells transfected with siDaam1 or miR-335 adopted a stellate morphology and collapsed
their actin stress fibers together with increased membrane ruffling. (E) Cell invasiveness was detected by transwell invasion assay. C6 cells were
transfected with 50 nM siDaam1 or miR-335 mimics for the indicated times. Results represent the means ± SD for three repeats. (*, p < 0.05;**,
p < 0.01). Original magnification in (D up-panel; E), 200 ×; (D down-panel), 630 ×.
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Figure 6 SiDaam1 reverses the anti-tumor effects of antagomir-335 in C6 cells. (A) SiDaam1 obviously abrogated upregulation of DAAM1
induced by antagomir-335 transfection. (B-E) siDaam1 counteracted the anti-tumor effects of antagomir-335. SiDaam1 significantly abrogated
antagomir-335-induced growth arrest (B), repression of colony formation(C), invasion inhibition (D) and caspase3/7 activity (E). C6 cells were
transfected with 50 nM siDaam1 and/or 100 nM antagomir-335 for the indicated times. Results represent the means ± SD for three repeats.
(***, p < 0.001). Original magnification in (D), 200 ×.
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Figure 7 MiR-335 inhibition suppresses tumor growth in vivo. (A-C) Pretreated effect of antagomir-335 on tumor formation in nude mouse
xenograft model. (A)Antagomir-NC-transfected and antagomir-335-transfected C6 cells were s.c. injected into the left (up-panel) and right
(down-panel) flanks of nude mice, respectively (n = 8). (B) Tumor volume was monitored during the time course of 19 days. (C) Tumor weight
was detected at the end of the study. (D-H) Therapeutic effect of antagomir-335 on tumor growth in nude mouse xenograft model. (D) Tumors
generated by C6 cells injection in nude mice were intratumorally injected with antagomir-NC (up-panel) and antagomir-335 (down-panel) for 2
weeks, respectively(n = 5). (E) Tumor volume was monitored during the time course of 4 weeks. (F) Tumor weight was detected at the end of
the study. (G) DAAM1 expression was detected by immunohistochemistry. (H) Apoptotic cells were detected by TUNEL assay. Data represent the
means ± SD. Statistical differences compared with the controls are given as **, P < 0.01; ***, P < 0.001. Original magnification in (G up-panel),
320 ×; Original magnification in (H), 400 ×.
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Both miR-335 and siDAAM1 promote growth and
invasion of human U87-MG astrocytoma cells
To test whether our findings extend to human astrocy-
toma cells, we first compared miR-335 expression
between human astrocytoma U87-MG cells and human
normal astrocyte HEB cells. Consistent with the C6
cells, the expression of miR-335 was markedly upregu-
lated in U87-MG astrocytoma cells (Figure 8A). Further-
more, ectogenic expression of miR-335 significantly
promoted viability of U87-MG cells in a time-dependent
manner (Figure 8B). And an enhanced colony formation
was further observed (Figure 8C). Importantly, this col-
ony-promoting effect was also detected by effective
DAAM1 abrogation (Figure 8C, D). Moreover, cells
transfected with miR-335 or siDAAM1 showed a loss of
actin stress fibers, adopting more of a stellate morphol-
ogy with an increase of actin-rich cell processes and
membrane ruffles (Figure 8E). We also observed that
both miR-335 and siDAAM1 efficiently accelerated the
invasiveness of U87-MG cells in vitro (Figure 8F). In
addition, the expression of DAAM1 was substantially
downregulated after miR-335 transfection (Figure 8G
left-panel). Moreover, the reciprocal expression pattern
between endogenous miR-335 and DAAM1 was further
confirmed in HEB and U87-MG cells (Figure 8G right-
panel). All of the above findings together with those
observed in C6 cells suggested that miR-335 might act
as an oncomiRNA both in rat and human malignant
astrocytoma pathgenesis.
MiR-335 inhibition induces apoptosis and suppresses
invasion in human U87-MG astrocytoma cells
The anti-tumor effects of miR-335 abrogation were further
investigated in U87-MG cells. As Figure 9A, B, C, shown,
antagomir-335 strongly inhibited viability, colony forma-
tion and invasion of U87-MG cells. Moreover, after expo-
sure to antagomir-335, the U87-MG cells displayed all of
the apoptotic morphological alterations such as shrinkage
of the cell, condensation of chromatin, and disintegration
of the cell into small fragments (Figure 9D, E). Consis-
tently, TUNEL assay showed an increased apoptosis in
antagomir-335 transfected U87-MG cells (Figure 9F). We
also observed caspase 3/7 activity was markedly enhanced
after 72 h antagomir-335 tranfection, confirming miR-335
abrogation could induce caspase-mediated apoptosis in
human astrocytoma cells (Figure 9G). In addition, the
expression of DAAM1 was substantially upregulated after
antagomir-335 transfection (Figure 9H left-panel). More-
over, the phosporylation of MLC (myosin light chain) was
also highly induced (Figure 9H right-panel). All of the
above findings seem to demonstrate that antagomir-335 is
able to induce apoptosis and suppress invasion in both rat
C6 and human U87-MG astrocytoma cells, which indi-
cates the anti-tumor effects of miR-335 abrogation are
evolutionarily conserved from rat to human in malignant
astrocytoma.
Discussion
Malignant astrocytomas are one of the leading causes of
cancer deaths in central nervous system characterized
by unlimited proliferation and progressive local invasion
[1,26]. Unfortunately, the underlying molecular mechan-
isms resulting in astrocytomagenesis and local invasion
remain obscure so far and stand for the major obstruc-
tion in finding novel therapeutic strategies [27]. In this
study, we found that miR-335 targeted a potential
tumor suppressor Daam1, which promoted several
oncogenic features such as growth and invasion in
astrocytoma cells. Furthermore, miR-335 inhibition
could effectively suppress growth and induce apoptosis
of astrocytoma cells both in vitro and in vivo. Impor-
tantly, the anti-tumor effects of miR-335 abrogation also
extended to human astrocytoma cells. Thus, miR-335
might act as an evolutionarily conserved oncomiRNA in
astrocytoma pathogenesis and represent a potential ther-
apeutic target for this highly aggressive and, as yet, ther-
apy-refractory tumor.
Genetic aberration patterns specific for different
grades of astrocytoma have been defined previously [12].
Gain of chromosome 7 with a hot spot at 7q32 appears
to be the most prominent aberration and an early event
in tumorigenesis of astrocytoma, whereas in glioblas-
toma multiforme, gain of 7p12 seems to be the most
frequently affected band on chromosome 7 [12]. We
found 8 expressed miRNAs (miR-593, miR-129-1, miR-
335, miR-182, miR-96, miR-183, miR-29a, miR-29b-1)
reside on 7q32, some of which have been investigated,
either as oncogenes or tumor suppressor genes [13-15].
It is becoming increasingly clear that chromosomal
abnormalities and/or epigenetic events contribute to
miRNA deregulation [28]. Our data showed that the
intronic miR-335, flanked by MEST imprinting gene in
the 7q32.2 region, was highly expressed in astrocytoma
cell lines and tissues. Intriguingly, genomic copy number
analysis revealed statistically significant amplification of
miR-335 locus in U87-MG cell line and II-III grade
malignant astrocytoma tissues (Additional file 2 Figure
S6). Moreover, we also determined the miR-335 expres-
sion level in glioblastoma multiforme T98G cell line,
and found that it was slightly upregulated compared to
HEB (Additional file 2 Figure S7). Loss of function
study also showed that inhibition of miR-335 in T98G
cells had little effect on their growth (Additional file 2
Figure S8). Therefore, we hypothesize that the observed
increased expression of miR-335 may partially result
from 7q32.2 regional amplification, and miR-335 may
act as an early promoter and a biomarker during tumor-
igenesis of astrocytoma.
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Figure 8 Both siDAAM1 and miR-335 promote growth and invasion of human astrocytoma U87-MG cells. (A) miR-335 expression in U87-
MG and HEB cells was detected by real-time qRT-PCR. (B) Cell viability was detected by MTT assay. (C) Effect of siDAAM1 or miR-335 transfection
on colony formation. (D) Effect of siDAAM1 transfection on DAAM1 protein expression. U87-MG cells were transfected with 50 nM siDAAM1 for
72 h. (E) Morphologic alteration (up-panel) and phallotoxins stained actin rearrangement (down-panel). Cells treated with siDAAM1 or miR-335
adopted a stellate morphology and collapsed their actin stress fibers together with increased membrane ruffling. (F) Cell invasiveness was
detected by transwell invasion assay. (G left-panel) Western blot analysis was used to detect DAAM1 protein expression in U87-MG cells 72 h
after transfection with 100 nM miR-335 mimics. (G right-panel) Endogenous DAAM1 expression in U87-MG and HEB cells was detected by
western blot. GFAP expression was used as a biomarker of normal astrocytes. Results represent the means ± SD for three repeats. (*, p < 0.05;**,
p < 0.01;***, P < 0.001). Original magnification in (E up-panel; F), 200 ×; (E down-panel), 400 ×.
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Figure 9 MiR-335 inhibition induces apoptosis and suppresses invasion of human astrocytoma U87-MG cells. (A) Time-dependent effect
of antagomir-335 on cell viability. U87-MG cells were transfected with 100 nM antagomir-335 for the indicated times. (B) Effect of antagomir-335
transfection on colony formation. (C) Cell invasiveness was detected by transwell invasion assay. U87-MG cells were transfected with 100 nM
antagomir-335 or antagomir-NC. Graph is the representative of three independent experiments. (D) Phase-contrast imaging and (E) Hoechest
33258 staining of U87-MG cells. (F) Apoptotic cells were detected by TUNEL assay. (G) Effect of antagomir-335 on caspase3/7 activity. U87-MG
cells were transfected with 100 nM antagomir-335 or antagomir-NC for 72 h. (H) Effect of antagomir-335 on expression of DAAM1 (left-panel)
and phosphorylation of MLC (right-panel) in U87-MG cells. Cells were transfected with 100 nM antagomir-335 or antagomir-NC for 48 h. Data
represent the means ± SD. Statistical differences compared with the controls are given as *, P < 0.05; **, p < 0.01; ***, P < 0.001. Original
magnification in (C, D, F), 200 ×; Original magnification in (E), 400 ×.
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To date, a panel of miRNA mutations or deletions
have been reported, either tumor suppressors or onco-
genes in multiple human cancers [5], including malig-
nant astrocytomas [29]. Even more, impairment of
microRNA regulatory network is considered as one of
the key mechanisms in astrocytoma pathogenesis [30].
With regard to miR-335, it is normally expressed in a
variety of human tissues and deregulated in several
types of tumors [31-34], suggesting complex biological
roles of this miRNA during tumorigenesis. Of particular
interest, miR-335 was recently reported to suppress
metastasis of human breast cancer via targeting of SO ×
4 and tenascin C, however, without affecting its prolif-
eration [17]. This finding is apparently in contradiction
with the function of miR-335 as an invasion promoter
in malignant astrocytomas. Due to the fact that one
miRNA can regulate more than one target gene, it is
possible to speculate the selection of genes that would
make major contributions to the phenotypes induced by
the miRNA may depend on the cellular microenviron-
ment. Therefore, we propose that the downregulation of
DAAM1 induced by miR-335 may play a predominant
role in mediating the pro-invasion effect of miR-335 in
astrocytoma cells. Furthermore, it is also demonstrated
that miR-335 regulates Rb1 and controls cell prolifera-
tion in a p53-dependent manner [18]. MiR-335 drives
hyperproliferation in the absence of p53 and induces
apoptosis and/or cell cycle arrest in the presence of
wide-type p53 [18]. In our study, we showed that miR-
335 strongly promoted growth of C6 and U87-MG
astrocytoma cells. However, it is well established that
both C6 and U87-MG cells express wild type (wt)-p53
[35,36]. Moreover, we further detected the effect of
miR-335 on Rb1 expression in astrocytoma cells. Sur-
prisingly, transient transfection of C6 and U87-MG cells
with miR-335 efficiently increased the Rb1 protein
levels, as detected by Western blotting (Additional file 2
Figure S9). This discrepancy is likely due to the differ-
ence in cell context, and suggests that altered expression
of this miRNA may have diverse effects in tumor cells.
In fact, the interaction between miRNA and its target
mRNA can be controlled by many factors. For example,
recent studies have shown that there are AU-rich ele-
ments (AREs) resided in the vicinity of the microRNA
target sites (seed sequence), and both AREs and seed
sequence are highly conserved throughout evolution in
mRNA 3’UTRs [37]. Intriguingly, two RNA binding pro-
teins HuR and Dnd1 have been identified to counteract
the function of miRNAs by binding AREs and blocking
miRNAs from associating with their target sites [38,39].
Even more, both miR-369-3 and let-7 have been shown
to activate target gene expression on cell cycle arrest by
recruiting specific proteins to AREs [37]. Thus, it is rea-
sonable to assume that astrocytoma cell-specific factors
bind and counteract miR-335 function in these cells.
Further experiments to clarify this discrepancy would be
of great interest.
Dishevelled-associated activator of morphogenesis 1
(Daam1), a member of the formin protein family acting
downstream of WNT signaling, plays an important role in
regulating the actin cytoskeleton via mediation of linear
actin assembly [40]. Previous functional studies of Daam1
suggest its essential roles in promoting proper cell polari-
zation, migration, proliferation and tissue morphogenesis
during embryonic development [41]. Inhibition of Daam1
results in an increase in cell migration of parietal endo-
derm [42] while activation of Daam1 suppresses endothe-
lial cell proliferation, migration and angiogenesis [43]. It is
also demonstrated that stably overexpressing Daam1
enhances myosin IIB stress fiber network which opposes
cell migration [41]. Additionally, Daam1 has been linked
to the control of cell behaviors by regulating downstream
Rho/ROCK [42]. It is well established that inhibition of
ROCK can promote motility of astrocytoma cells via actin
rearrangement [44]. In line with these observations, our
data showed that both miR-335 and knockdown of Daam1
(siDaam1) efficiently promoted invasion of C6 and U87-
MG astrosytoma cells, and an alteration of cell morphol-
ogy as well as a loss of actin stress fibers together with
induction of actin-positive membrane ruffles were also
observed, indicating that the actin rearrangement may
contribute to the pro-invasive effect of miR-335 in astrocy-
toma cells. Furthermore, ROCK is recognized as a major
regulator of the morphological events that occur during
the execution phase of apoptosis, including cell contrac-
tion, dynamic membrane blebbing, nuclear disintegration,
and fragmentation of apoptotic cells into apoptotic bodies.
It is reported that activation or overexpression of ROCK
increases MLC (myosin light chain) phosphorylation and
subsequently results in actomyosin contractility, mem-
brane blebbing and apoptosis [45,46]. In our study, we
found that antagomir-335 dramatically upregulated
DAAM1 protein, meanwhile, the phosphorylation of MLC
was also extremely stimulated both in C6 and U87-MG
cells. These results suggest that antagomir-335 induced
apoptosis may partially through the increase of DAAM1
which, in turn enhances MLC phosphorylation. In addi-
tion, it is noteworthy that siDaam1 was able to mimic the
oncogenic behaviors of miR-335; however, it could only
counteract partially the anti-tumor effects of antagomir-
335. Therefore, it is likely that miR-335 has effects inde-
pendent of DAAM1. Alternatively, it would be reasonable
that the downregulation of DAAM1 could simply coop-
erate with the concomitant attenuation of other miR-335
targets.
Besides in vitro study, we also found that antagomir-335
could effectively inhibit tumor growth in both pretreated
and therapeutic xenograft models. Similar to targeted
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therapies that tackle a gain-of-function in cancer, such as
EGFR inhibitors, the introduction of the antagonist speci-
fic to oncomiRNA miR-335 interferes with the oncogenic
properties of astrocytoma cells and induces therapeutic
responses. This “miRNA targeting therapy” has been given
more and more attention and successfully demonstrated
in several human diseases [47-50], indicating a potential
application of this approach in clinical settings. While our
results presented here suggest that antagomir-335 may
prove useful in the treatment of astrocytoma, the challenge
for this approach will be the successful delivery of the
miRNA antagonist to the tumor cells. Local delivery of
synthetic antagomir-335 by intratumoral injections
resulted in strong inhibition of tumor growth. Neverthe-
less, this delivery route might be inadequate in a clinical
setting as peripheral tumor cells remained present. There-
fore, a delivery technology that facilitates universal access
to all tumor cells, such as a systemic delivery route, might
be needed to make the therapy more efficacious.
Conclusions
In summary, our present study uncovered an oncogenic
function of miR-335 resided on chromosome 7q32.2
that amplified frequently in astrocytoma, which may
provide a novel insight to its molecular etiology. This
effect may be caused by WNT/PCP signaling inhibition
ascribed to the restrain of DAAM1 protein. Of note,
miR-335 abrogation displayed notable anti-tumor effects
both in vitro and in vivo. Significantly, the anti-tumor
effects also extended to human malignant astrocytoma,
indicating the evolutionarily conserved function of miR-
335 and a potential application of targeting miR-335 in
the therapy of malignant astrocytoma.
Additional material
Additional file 1: Table S1. Patients’ characteristics of the tumor
samples used in our experiment.
Additional file 2. Supplementary Figures: Figure S1. MiR-335 fails to
transform but enhances viability and invasiveness of normal astrocytes.
(A) Cell viability was detected by MTT assay. (B) Cell invasiveness was
determined by transwell assay. (C) Effect of miR-335 transfection on
colony formation. Cells were transfected with 50 nM miR-335 mimics
for the indicated times. Results represent the means ± SD for three
repeats. (*, P < 0.05;**, P < 0.01). Original magnification in (B), 200 ×.
Figure S2. Putative miR-335 binding sites in the 3’-UTR of respective
genes. Figure S3. Effect of miR-335 overexpression on endogenous
Daam1 mRNA level. Rat normal astrocytes were transfected with 50 nM
miR-335 mimics for 48 h. Daam1 mRNA was detected by qRT-PCR.
Figure S4. Effect of miR-335 overexpression on endogenous RASA1 and
MAP2 protein levels. C6 cells were transfected with 50 nM miR-335
mimics for 72 h. Western blot was used to detect the protein levels of
respective genes. Figure S5. Effect of antagomir-335 on tumor
metastasis in nude mouse xenograft model. The same side anterior
flank metastasis was indicated by arrows (up-panel) in antagomir-NC
group. The ratio of metastasis was quantified in two groups (down-
panel). Figure S6. Genomic copy number analysis reveals statistically
significant amplification of miR-335 locus in U87-MG cell line and II-III
grade malignant astrocytoma tissues. Quantitative genomic real-time
PCR was performed on DNA from HEB, U87-MG cell lines as well as
normal brain (N) and II-III grade malignant astrocytoma tissues. Figure
S7. MiR-335 expression analysis in human astrocytes HEB and
glioblastoma multiform T98G cells. Figure S8. Effect of miR-335
abrogation on cell growth. T98G cells were transfected with 100 nM
antagomir-335 for the indicated times. Cell viability was detected with
MTT assay. Figure S9. Effect of miR-335 on Rb1 expression in C6 and
U87-MG astrocytoma cells. Cells were transfected with 50 nM miR-335
for 48 h. Rb1 protein was detected by Western blot.
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